In short
A new clinical trial is underway to assess the potential of INT-787, a novel drug designed to treat severe alcohol-associated hepatitis (sAH). This Phase 2a study aims to determine the safety, effectiveness, and optimal dosage of INT-787 in patients with this serious liver condition. The trial will compare INT-787 to a placebo, providing valuable insights into its potential as a treatment option for those suffering from sAH.
At a glance
- Study Type
- Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation
- Drug
- INT-787
- Condition
- Severe Alcohol-Associated Hepatitis (sAH)
- Primary Outcome
- Lille model response based on Lille score
- Key Secondary Outcomes
- Change in MELD score, change in total bilirubin, mortality/transplantation rates
- Safety Measures
- Monitoring of TEAEs, SAEs, AESIs, and infectious adverse events
- Pharmacokinetic Measures
- Total exposure (AUC), Maximum Plasma Concentration (Cmax), Elimination half-life
What is INT-787?
INT-787 is a new drug being studied for the treatment of severe alcohol-associated hepatitis (sAH). It is currently undergoing a Phase 2a clinical trial, which means it's in the early stages of testing in humans to determine its safety and effectiveness. This drug is being developed as a potential new treatment option for patients with this serious liver condition.
What Condition Does INT-787 Treat?
INT-787 is specifically being studied to treat severe alcohol-associated hepatitis (sAH). This is a serious form of liver damage caused by excessive alcohol consumption. In sAH, the liver becomes inflamed and damaged, leading to various health complications. It's a life-threatening condition that currently has limited treatment options, making the development of new drugs like INT-787 crucial.
Details of the FRESH Study
The clinical trial for INT-787 is called the FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study. Here are some key details about the study:
- Type of study: It's a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-escalation, proof-of-concept study. This means:
- It's an early-phase study to test the drug's effectiveness and safety.
- Participants are randomly assigned to either receive INT-787 or a placebo (a substance with no active ingredients).
- Neither the participants nor the researchers know who is receiving the actual drug or the placebo (this is what "double-blind" means).
- The study is being conducted at multiple medical centers.
- Different doses of the drug will be tested to find the most effective and safe dose.
- Purpose: The study aims to assess the safety, tolerability, effectiveness, and how the body processes INT-787 (known as pharmacokinetics) in patients with severe alcohol-associated hepatitis.
How INT-787 Works
While the exact mechanism of INT-787 is not detailed in the provided information, we can infer some details based on the study name. The "FXR" in the study title likely refers to the Farnesoid X Receptor, which is an important regulator in the liver. FXR activation has been shown to have beneficial effects on liver health, including reducing inflammation and fibrosis (scarring of the liver). INT-787 may work by targeting this receptor to improve liver function in patients with severe alcohol-associated hepatitis.
Expected Benefits of INT-787
The researchers are looking at several ways to measure if INT-787 is effective:
- Lille model response: This is a scoring system used to predict the outcome of patients with severe alcoholic hepatitis. A lower score (less than 0.45) indicates a better response to treatment.
- Change in MELD score: The Model for End-Stage Liver Disease (MELD) score is used to assess the severity of liver disease. A decrease in this score would indicate improvement in liver function.
- Change in total bilirubin: Bilirubin is a substance produced when the liver breaks down old red blood cells. High levels can indicate liver problems, so a decrease would be a positive sign.
- Mortality or liver transplantation rates: The study will look at whether INT-787 can reduce the number of deaths or need for liver transplants compared to placebo.
Safety Monitoring
The safety of INT-787 is a crucial aspect of the study. The researchers will be closely monitoring:
- Treatment emergent adverse events (TEAEs): Any new medical problems that occur during the study.
- Serious adverse events (SAEs): Any severe medical issues that arise.
- Adverse events of special interest (AESIs): Specific medical issues that the researchers are particularly watching for.
- Infectious adverse events: Any infections that occur during the study.
Future Implications
If INT-787 proves to be safe and effective in this study, it could potentially become a new treatment option for patients with severe alcohol-associated hepatitis. This would be a significant development, as current treatment options for this condition are limited. The study will also provide valuable information about how the drug behaves in the body of patients with advanced liver disease, which will be crucial for planning future clinical trials.